UK-CAB 16 – HIV related brain impairment – SMART study – Tibotec
24 February 2006
Program for the meeting
Reading materials
Post meeting documents
SMART PowerPoint Slides [121 Kb]
Programme
09:00 – 09:30 | Registration and coffee |
09:30 – 10:30 | CAB Future meetings – Robert James / Mark McPherson |
10:30 – 11:00 | Break |
11:00 – 12:30 | HIV Related Brain Impairment – Heather George, Brighton |
12:30 – 13:30 | Lunch |
13:30 – 15:00 | Company meeting: Tibotec |
15:00 – 15:30 | Break |
15:30 – 15:45 | National Treatment Support Project – Elijah Amooti |
15:45 – 16:15 | SMART Study – Simon Collins |
16:15 – 17:00 | Feedback from Meetings and Conferences / Future Meetings |
Reading materials
Tibotec
The two links to Tibotec articles written by Mark Mascolini for NATAP, were both in the Jan/Feb issue of HTB.
HTB Volume 7 Number 1/2 Page 11 – The TMC125: some good and bad news:
The issue is related to potency, since the stopping of one recent trial.
HTB Volume 7 Number 1/2 Page 20 – Understanding TMC114 power against resistant HIV
The discussion is about potency, with or without T-20, TMC-114 is now on expanded access in the UK.
HIV dementia
http://www.emedicine.com/neuro/topic447.htm
This site offers a background into neurological complications from HIV, provides simple information about how it occurs, the frequency, diagnosis and treatment. There are also a range of links to other related topics.
Update on the Neurological Manifestations of HIV
Justin McArthur, MBBS, MPH
PRN Notebook, www.prn.org
http://www.prn.org/prn_nb_cntnt/vol10/num3/mcarthur_frm.htm
or
PDF File [192 Kb]
AIDS Dementia Complex
Dementia is a brain disorder that affects a person’s ability to think clearly and can impact his or her daily activities. AIDS dementia complex (ADC)-dementia caused by HIV infection-is a complicated syndrome made up of different nervous system and mental symptoms. These symptoms are somewhat common in people with HIV disease.
Project Inform factsheet, April 2002
http://www.projinf.org/fs/dementia.html
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.